Copyright © 2013 Alessandro Santoro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In a 61-year-old woman with well controlled arterial hypertension, hypercholesterolemia, and smoke and suffering from recurrent angina pectoris despite angiographically normal epicardial coronary vessels and maximal therapy, the replacement of nitrates with novel antiangina drug ranolazine, after 6-month therapy, induced a complete relief of angina and a relevant rising of the transthoracic Doppler-derived coronary flow reserve (CFR). The present clinical case underlines therefore how in...
Introduction: We aimed to assess if ranolazine would improve angina symptoms among patients with doc...
It has been suggested that one mechanism by which ranolazine protects the ischemic/reperfused heart ...
Contains fulltext : 52580.pdf (publisher's version ) (Closed access)BACKGROUND: Ra...
In a 61-year-old woman with well controlled arterial hypertension, hypercholesterolemia, and smoke a...
Adriano AM Truffa, L Kristin Newby, Chiara MelloniDuke Clinical Research Institute and Department of...
Coronary heart disease is a global malady and it is the leading cause of death in the United States....
Coronary heart disease is the major cause of morbidity and mortality throughout the world, and is re...
ObjectivesWe conducted a pilot study for a large definitive clinical trial evaluating the impact of ...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
ObjectivesThis study examined the hypothesis that the improvement in myocardial blood flow (MBF) wit...
Mortality rates attributable to coronary heart disease have declined in recent years, possibly relat...
Ranolazine is a piperazine derivative approved as an antianginal. Primarily used as a second-line an...
We report the case of a 59-year-old woman who presented with symptoms of angina that was refractory ...
Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is...
Introduction: We aimed to assess if ranolazine would improve angina symptoms among patients with doc...
It has been suggested that one mechanism by which ranolazine protects the ischemic/reperfused heart ...
Contains fulltext : 52580.pdf (publisher's version ) (Closed access)BACKGROUND: Ra...
In a 61-year-old woman with well controlled arterial hypertension, hypercholesterolemia, and smoke a...
Adriano AM Truffa, L Kristin Newby, Chiara MelloniDuke Clinical Research Institute and Department of...
Coronary heart disease is a global malady and it is the leading cause of death in the United States....
Coronary heart disease is the major cause of morbidity and mortality throughout the world, and is re...
ObjectivesWe conducted a pilot study for a large definitive clinical trial evaluating the impact of ...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
Chronic angina represents a major burden for public health systems because of its poor prognosis and...
ObjectivesThis study examined the hypothesis that the improvement in myocardial blood flow (MBF) wit...
Mortality rates attributable to coronary heart disease have declined in recent years, possibly relat...
Ranolazine is a piperazine derivative approved as an antianginal. Primarily used as a second-line an...
We report the case of a 59-year-old woman who presented with symptoms of angina that was refractory ...
Ranolazine is an antianginal and works by inhibiting late-sodium current (INaL). However, its use is...
Introduction: We aimed to assess if ranolazine would improve angina symptoms among patients with doc...
It has been suggested that one mechanism by which ranolazine protects the ischemic/reperfused heart ...
Contains fulltext : 52580.pdf (publisher's version ) (Closed access)BACKGROUND: Ra...